噻托溴銨對不同表型慢性阻塞性肺疾病患者的療效觀察_《華西醫學》

作者：

李繼瓊

成都市第二人民醫院呼吸內科（成都，610017）;

關鍵詞：

慢性阻塞性肺疾病肺功能運動耐量噻托溴銨

DOI：

10.7507/1002-0179.20130056

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的　評價噻托溴銨對不同表型慢性阻塞性肺疾病（COPD）患者的療效。方法　選取2008年10月－2010年5月COPD患者81例，根據胸部高分辨率CT上的形態表現分型，以氣道病變為主型納入A組，以肺氣腫為主型納入B組，按方案吸入噻托溴銨，在給藥前后分別測定肺功能、圣?喬治呼吸問卷評分（SGRQ）及6 min步行距離。結果　用藥3個月后A組的第1秒用力肺活量（FEV1）、用力肺活量（FVC）、FEV1/FVC及FEV1占預計值（%）比B組明顯提高，兩組比較差異有統計學意義（P＜0.05），SGRQ評分比較B組明顯下降，運動耐力（6 min步行距離）增加（P＜0.05）。結論　噻托溴銨在COPD的治療中，針對不同的表型，其療效不同。

引用本文： 李繼瓊. 噻托溴銨對不同表型慢性阻塞性肺疾病患者的療效觀察. 華西醫學, 2013, 28(2): 172-174. doi: 10.7507/1002-0179.20130056 復制

1.	Makita H, Nasuhara Y, Nagai K, et al. Characterization of phenotypes based on severity of emphysema in chronic obstruction pulmonary disease[J]. Thorax, 2007, 62(11): 932-937.
2.	中華醫學會呼吸病學分會慢性阻塞性肺疾病學組．慢性阻塞性肺疾病診治指南(2007年修訂版)[J]．中華結核和呼吸雜志, 2007, 30(1): 8-17．.
3.	Celli BR, Roger S. Mitchell lecture. Chronic obstructive pulmonary disease phenotype and their clinic relevance[J]. Proc Am Thorac Soc, 2006, 3(6): 461-465．.
4.	Matsuoka S, Yamashiro T, Washko GR, et al. Quantitative CT assessment of chronic obstructive pulmonary disease[J]. Radiographics, 2010, 30(1): 55-66．.
5.	Tatsumi K, Kasahana Y, Kurosu K,et al. Clinical phenotypes of COPD：resulys of a Japanses epidemioligie survey[J]. Respiralogy, 2004, 9(3): 331-336.
6.	程艷慧, 何東初. COPD發病機制分子生物學的最新研究進展[J]. 臨床肺科雜志, 2010, 15(2): 232-233.
7.	Fujimoto K, Kitaguchi Y, Kubo K, et al. Clinical analysis of chronicobstructive pulmonary disease phenotypes classified using highresolution computed tomography[J]．Respirology, 2006, 11(6): 731-740．.
8.	Nakono Y, Muro S, Sakai H, et al. Computed tomographic measurement of airway dimenstions and emphysema in smokers：correlation with lung function[J]．Am J Respir Crit Care Med, 2000, 162(3 Pt 1): 1102-1108．.
9.	Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD[J]. Chest, 2005, 127(3): 809-817．.
10.	Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches[J]. Eur Respir, 2005, 25(6): 1084-1106．.
11.	Casaburi R, Mahler DA, Jones PW, et al. A Long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease[J]．Eur Respir J, 2002, 19(2): 217-224．.
12.	Tashkin DP, Celli B, Senn S, et al. A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease[J]. N Engl J Med, 2008, 359(15): 1543-1554．.
13.	王長征．藥物治療能改變慢性阻塞性肺疾病患者肺功能的下降速率嗎? [J]. 中國呼吸與危重監護雜志, 2009, 8(1): l-2．.
14.	Saito Y, Azuma A, Morimoto T, et al. Tiotropium ameliorates symptoms in patients with chronic airway mucus hypersecretion which is resistant to Macrolide therapy[J]. Intern Med, 2008, 47(7): 585-591．.
15.	Profita M, Bonanno A, Siena L, et al. Acetylcholine mediates the release of IL-8 in human bronchial cells by a NFκB/ERK-dependent mechanism[J]. Eur J Pharmacol, 2008, 582(1-3): 145-l53．.
16.	Bühling F, Lieder N, Kuhlmann UC, et al. Tiotropium suppresses acetylcholine-induced release of chemotactic mediators in vitro[J]. Respir Med, 2007, l01(11): 2386-2394．.

1. 　Makita H, Nasuhara Y, Nagai K, et al. Characterization of phenotypes based on severity of emphysema in chronic obstruction pulmonary disease[J]. Thorax, 2007, 62(11): 932-937.
2. 　中華醫學會呼吸病學分會慢性阻塞性肺疾病學組．慢性阻塞性肺疾病診治指南(2007年修訂版)[J]．中華結核和呼吸雜志, 2007, 30(1): 8-17．.
3. 　Celli BR, Roger S. Mitchell lecture. Chronic obstructive pulmonary disease phenotype and their clinic relevance[J]. Proc Am Thorac Soc, 2006, 3(6): 461-465．.
4. 　Matsuoka S, Yamashiro T, Washko GR, et al. Quantitative CT assessment of chronic obstructive pulmonary disease[J]. Radiographics, 2010, 30(1): 55-66．.
5. 　Tatsumi K, Kasahana Y, Kurosu K,et al. Clinical phenotypes of COPD：resulys of a Japanses epidemioligie survey[J]. Respiralogy, 2004, 9(3): 331-336.
6. 　程艷慧, 何東初. COPD發病機制分子生物學的最新研究進展[J]. 臨床肺科雜志, 2010, 15(2): 232-233.
7. 　Fujimoto K, Kitaguchi Y, Kubo K, et al. Clinical analysis of chronicobstructive pulmonary disease phenotypes classified using highresolution computed tomography[J]．Respirology, 2006, 11(6): 731-740．.
8. 　Nakono Y, Muro S, Sakai H, et al. Computed tomographic measurement of airway dimenstions and emphysema in smokers：correlation with lung function[J]．Am J Respir Crit Care Med, 2000, 162(3 Pt 1): 1102-1108．.
9. 　Casaburi R, Kukafka D, Cooper CB, et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD[J]. Chest, 2005, 127(3): 809-817．.
10. 　Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches[J]. Eur Respir, 2005, 25(6): 1084-1106．.
11. 　Casaburi R, Mahler DA, Jones PW, et al. A Long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease[J]．Eur Respir J, 2002, 19(2): 217-224．.
12. 　Tashkin DP, Celli B, Senn S, et al. A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease[J]. N Engl J Med, 2008, 359(15): 1543-1554．.
13. 　王長征．藥物治療能改變慢性阻塞性肺疾病患者肺功能的下降速率嗎? [J]. 中國呼吸與危重監護雜志, 2009, 8(1): l-2．.
14. 　Saito Y, Azuma A, Morimoto T, et al. Tiotropium ameliorates symptoms in patients with chronic airway mucus hypersecretion which is resistant to Macrolide therapy[J]. Intern Med, 2008, 47(7): 585-591．.
15. 　Profita M, Bonanno A, Siena L, et al. Acetylcholine mediates the release of IL-8 in human bronchial cells by a NFκB/ERK-dependent mechanism[J]. Eur J Pharmacol, 2008, 582(1-3): 145-l53．.
16. 　Bühling F, Lieder N, Kuhlmann UC, et al. Tiotropium suppresses acetylcholine-induced release of chemotactic mediators in vitro[J]. Respir Med, 2007, l01(11): 2386-2394．.

《華西醫學》

噻托溴銨對不同表型慢性阻塞性肺疾病患者的療效觀察

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

《華西醫學》

噻托溴銨對不同表型慢性阻塞性肺疾病患者的療效觀察

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

上一篇

下一篇

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料